The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Histone Deacetylase Inhibitor Romidepsin Induces HIV Expression in CD4 T Cells from Patients on Suppressive Antiretroviral Therapy at Concentrations Achieved by Clinical Dosing
Open accessAbstract
Persistent latent reservoir of replication-competent proviruses in memory CD4 T cells is a major obstacle to curing HIV infection. Pharmacological activation of HIV expression in latently infected cells is being explored as one of the strategies to deplete the latent HIV reservoir. In this study, we characterized the ability of romidepsin (RMD), a histone deacetylase inhibitor approved for the treatment of T-cell lymphomas, to activate the expression of latent HIV. In an in vitro T-cell model of HIV latency, RMD was the most potent inducer of HIV (EC50 = 4.5 nM) compared with vorinostat (VOR; EC50 = 3,950 nM) and other histone deacetylase (HDAC) inhibitors in clinical development including panobinostat (PNB; EC50 = 10 nM). The HIV induction potencies of RMD, VOR, and PNB paralleled their inhibitory activities against multiple human HDAC isoenzymes. In both resting and memory CD4 T cells isolated from HIV-infected patients on suppressive combination antiretroviral therapy (cART), a 4-hour exposure to 40 nM RMD induced a mean 6-fold increase in intracellular HIV RNA levels, whereas a 24-hour treatment with 1 µM VOR resulted in 2- to 3-fold increases. RMD-induced intracellular HIV RNA expression persisted for 48 hours and correlated with sustained inhibition of cell-associated HDAC activity. By comparison, the induction of HIV RNA by VOR and PNB was transient and diminished after 24 hours. RMD also increased levels of extracellular HIV RNA and virions from both memory and resting CD4 T-cell cultures. The activation of HIV expression was observed at RMD concentrations below the drug plasma levels achieved by doses used in patients treated for T-cell lymphomas. In conclusion, RMD induces HIV expression ex vivo at concentrations that can be achieved clinically, indicating that the drug may reactivate latent HIV in patients on suppressive cART.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation
Chomont, N., El-Far, M., Ancuta, P., Trautmann, L., Procopio, F. A., Yassine-Diab, B., Boucher, G., Boulassel, M.-R., Ghattas, G., Brenchley, J. M., et al. (2009) · Nature Medicine · doi:10.1038/nm.1972 · Cited by 1,722
Siliciano, J. D., Kajdas, J., Finzi, D., Quinn, T. C., Chadwick, K., Margolick, J. B., Kovacs, C., Gange, S. J., & Siliciano, R. F. (2003) · Nature Medicine · doi:10.1038/nm880 · Cited by 1,703
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
(2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,678
Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure
Ho, Y.-C., Shan, L., Hosmane, N. N., Wang, J., Laskey, S. B., Rosenbloom, D. I. S., Lai, J., Blankson, J. N., Siliciano, J. D., & Siliciano, R. F. (2013) · Cell · doi:10.1016/j.cell.2013.09.020 · Cited by 1,405
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
Archin, N. M., Liberty, A. L., Kashuba, A. D., Choudhary, S. K., Kuruc, J. D., Crooks, A. M., Parker, D. C., Anderson, E. M., Kearney, M. F., Strain, M. C., et al. (2012) · Nature · doi:10.1038/nature11286 · Cited by 1,139
Self-citationThe Challenge of Finding a Cure for HIV Infection
Richman, D. D., Margolis, D. M., Delaney, M., Greene, W. C., Hazuda, D., & Pomerantz, R. J. (2009) · Science · doi:10.1126/science.1165706 · Cited by 846
(2002) · PubMed · Cited by 732
Shan, L., Deng, K., Shroff, N. S., Durand, C. M., Rabi, S. A., Yang, H.-C., Zhang, H., Margolick, J. B., Blankson, J. N., & Siliciano, R. F. (2012) · Immunity · doi:10.1016/j.immuni.2012.01.014 · Cited by 714
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
Palmer, S., Maldarelli, F., Wiegand, A., Bernstein, B., Hanna, G. J., Brun, S. C., Kempf, D. J., Mellors, J. W., Coffin, J. M., & King, M. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800050105 · Cited by 638
Self-citationComparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies
Eriksson, S., Graf, E. H., Dahl, V., Strain, M. C., Yukl, S. A., Lysenko, E. S., Bosch, R. J., Lai, J., Chioma, S., Emad, F., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003174 · Cited by 567
Raffi, F., Rachlis, A., Stellbrink, H.-J., Hardy, W. D., Torti, C., Orkin, C., Bloch, M., Podzamczer, D., Pokrovsky, V., Pulido, F., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61853-4 · Cited by 548
Palmer, S., Kearney, M., Maldarelli, F., Halvas, E. K., Bixby, C. J., Bazmi, H., Rock, D., Falloon, J., Davey, R. T., Dewar, R. L., et al. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.1.406-413.2005 · Cited by 506
Self-citationSandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 502
UEDA, H., NAKAJIMA, H., HORI, Y., FUJITA, T., NISHIMURA, M., GOTO, T., & OKUHARA, M. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.301 · Cited by 489
Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma
Piekarz, R. L., Frye, R., Prince, H. M., Kirschbaum, M. H., Zain, J., Allen, S. L., Jaffe, E. S., Ling, A., Turner, M., Peer, C. J., et al. (2011) · Blood · doi:10.1182/blood-2010-10-312603 · Cited by 488
Redefining the Viral Reservoirs that Prevent HIV-1 Eradication
Eisele, E., & Siliciano, R. F. (2012) · Immunity · doi:10.1016/j.immuni.2012.08.010 · Cited by 474
NF‐κB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation
Williams, S. A., Chen, L., Kwon, H., Ruiz‐Jarabo, C. M., Verdin, E., & Greene, W. C. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7600900 · Cited by 430
Chun, T.-W., Davey, R. T., Ostrowski, M., Shawn Justement, J., Engel, D., Mullins, J. I., & Fauci, A. S. (2000) · Nature Medicine · doi:10.1038/77481 · Cited by 404
DeJesus, E., Rockstroh, J. K., Henry, K., Molina, J.-M., Gathe, J., Ramanathan, S., Wei, X., Yale, K., Szwarcberg, J., White, K., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60918-0 · Cited by 347
Messi, M., Giacchetto, I., Nagata, K., Lanzavecchia, A., Natoli, G., & Sallusto, F. (2003) · Nature Immunology · doi:10.1038/ni872 · Cited by 346
Roger, T., Lugrin, J., Le Roy, D., Goy, G., Mombelli, M., Koessler, T., Ding, X. C., Chanson, A.-L., Reymond, M. K., Miconnet, I., et al. (2011) · Blood · doi:10.1182/blood-2010-05-284711 · Cited by 341
Induction of HIV-1 latency and reactivation in primary memory CD4+ T cells
Bosque, A., & Planelles, V. (2009) · Blood · doi:10.1182/blood-2008-07-168393 · Cited by 340
Expression of Latent HIV Induced by the Potent HDAC Inhibitor Suberoylanilide Hydroxamic Acid
Archin, N. M., Espeseth, A., Parker, D., Cheema, M., Hazuda, D., & Margolis, D. M. (2009) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2008.0191 · Cited by 336
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs
Coiras, M., López-Huertas, M. R., Pérez-Olmeda, M., & Alcamí, J. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2223 · Cited by 288
Epigenetic Silencing of HIV-1 by the Histone H3 Lysine 27 Methyltransferase Enhancer of Zeste 2
Friedman, J., Cho, W.-K., Chu, C. K., Keedy, K. S., Archin, N. M., Margolis, D. M., & Karn, J. (2011) · Journal of Virology · doi:10.1128/jvi.00836-11 · Cited by 284
Colin, L., & Van Lint, C. (2009) · Retrovirology · doi:10.1186/1742-4690-6-111 · Cited by 222
Jiang, G., Espeseth, A., Hazuda, D. J., & Margolis, D. M. (2007) · Journal of Virology · doi:10.1128/jvi.01208-07 · Cited by 218
Xing, S., Bullen, C. K., Shroff, N. S., Shan, L., Yang, H.-C., Manucci, J. L., Bhat, S., Zhang, H., Margolick, J. B., Quinn, T. C., et al. (2011) · Journal of Virology · doi:10.1128/jvi.02033-10 · Cited by 197
Rasmussen, T. A., Søgaard, O. S., Brinkmann, C., Wightman, F., Lewin, S. R., Melchjorsen, J., Dinarello, C., Østergaard, L., & Tolstrup, M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.23800 · Cited by 193
Romidepsin: a novel histone deacetylase inhibitor for cancer
Bertino, E. M., & Otterson, G. A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.594437 · Cited by 166
Bouchat, S., Gatot, J., Kabeya, K., Cardona, C., Colin, L., Herbein, G., Wit, S. D., Clumeck, N., Lambotte, O., Rouzioux, C., et al. (2012) · AIDS · doi:10.1097/qad.0b013e32835535f5 · Cited by 155
Wightman, F., Ellenberg, P. C., Churchill, M. J., & Lewin, S. R. (2011) · Immunology and Cell Biology · doi:10.1038/icb.2011.95 · Cited by 133
Histone Deacetylase Inhibitors for Purging HIV-1 from the Latent Reservoir
Matalon, S., Rasmussen, T. A., & Dinarello, C. A. (2011) · Molecular Medicine · doi:10.2119/molmed.2011.00076 · Cited by 113
Smalls-Mantey, A., Doria‐Rose, N. A., Klein, R. M., Patamawenu, A. A., Migueles, S. A., Ko, S., Hallahan, C. W., Wong, H. C., Liu, B., You, L., et al. (2012) · Journal of Virology · doi:10.1128/jvi.00287-12 · Cited by 110
Combinatorial Latency Reactivation for HIV-1 Subtypes and Variants
Burnett, J., Lim, K., Calafi, A., Rossi, J. J., Schaffer, D. V., & Arkin, A. P. (2010) · Journal of Virology · doi:10.1128/jvi.00161-10 · Cited by 106
Iglesias-Ussel, M. D., Vandergeeten, C., Marchionni, L., Chomont, N., & Romerio, F. (2013) · Journal of Virology · doi:10.1128/jvi.01297-13 · Cited by 98
Alvarez-Breckenridge, C. A., Yu, J., Price, R. L., Wei, M., Wang, Y., Nowicki, M. O., Ha, Y. P., Bergin, S. M., Hwang, C., Fernández, S., et al. (2012) · Journal of Virology · doi:10.1128/jvi.05545-11 · Cited by 96
Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells
Bosque, A., & Planelles, V. (2010) · Methods · doi:10.1016/j.ymeth.2010.10.002 · Cited by 96
Histone Deacetylase Inhibitors Impair Antibacterial Defenses of Macrophages
Mombelli, M., Lugrin, J., Rubino, I., Chanson, A.-L., Giddey, M., Calandra, T., & Roger, T. (2011) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir553 · Cited by 89
HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation
Sweet, M. J., Shakespear, M. R., Kamal, N. A., & Fairlie, D. P. (2011) · Immunology and Cell Biology · doi:10.1038/icb.2011.88 · Cited by 81
Frequent polymorphism at drug resistance sites in HIV-1 protease and reverse transcriptase
Kearney, M. F., Palmer, S., Maldarelli, F. M., Shao, W., Polis, M. A., Mican, J. M., Rock-Kress, D., Margolick, J. B., Coffin, J. M., & Mellors, J. W. (2008) · AIDS · doi:10.1097/qad.0b013e3282f29478 · Cited by 80
Self-citationAltering cell death pathways as an approach to cure HIV infection
Badley, A. D., Sainski, A. M., Wightman, F., & Lewin, S. R. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.248 · Cited by 78
Edelstein, L. C., Micheva-Viteva, S., Phelan, B. D., & Dougherty, J. P. (2009) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2008.0294 · Cited by 74
Kelly‐Sell, M. J., Kim, Y. H., Straus, S., Benoit, B. M., Harrison, C., Sutherland, K., Armstrong, R. J., Weng, W., Showe, L. C., Wysocka, M., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.23112 · Cited by 70
HIV-1 eradication strategies: design and assessment
Siliciano, J. D., & Siliciano, R. F. (2013) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e328361eaca · Cited by 65
Doherty, R., O’Farrelly, C., & Meade, K. G. (2013) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2013.05.004 · Cited by 46
Xing, S., Bhat, S., Shroff, N. S., Zhang, H., Lopez, J. A., Margolick, J. B., Liu, J. O., & Siliciano, R. F. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr496 · Cited by 41
Kearney, M. F., Spindler, J., Shao, W., Maldarelli, F. M., Palmer, S., Hu, S.-L., Lifson, J. D., KewalRamani, V. N., Mellors, J. W., Coffin, J. M., et al. (2010) · Journal of Virology · doi:10.1128/jvi.01701-10 · Cited by 39
Self-citationImmunomodulatory Effects of Histone Deacetylase Inhibitors
Licciardi, P. V., Ververis, K., Tang, M. L. K., El‐Osta, A., & Karagiannis, T. C. (2013) · Current Molecular Medicine · doi:10.2174/1566524011313040013 · Cited by 37
The latent reservoir for HIV-1 in resting CD4+ T cells: a barrier to cure.
Siliciano, J. D., & Siliciano, R. F. (2006) · PubMed · doi:10.1097/01.coh.0000209582.82328.b8 · Cited by 37
Histone deacetylase inhibitor suppresses virus-induced proinflammatory responses and type 1 diabetes
Hara, N., Alkanani, A. K., Dinarello, C. A., & Zipris, D. (2013) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1078-1 · Cited by 32
Monoclonal antibodies in oncology therapeutics: present and future indications
Bhutani, D., & Vaishampayan, U. N. (2013) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.758705 · Cited by 28
Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4+ T cells
Beliakova‐Bethell, N., Zhang, J. X., Singhania, A., Lee, V., Terry, V. H., Richman, D. D., Spina, C. A., & Woelk, C. H. (2012) · AIDS · doi:10.1097/qad.0b013e32835b3e26 · Cited by 25
Self-citation
Cited by
Rasmussen, T. A., Tolstrup, M., Brinkmann, C. R., Olesen, R., Erikstrup, C., Solomon, A., Winckelmann, A., Palmer, S., Dinarello, C., Buzon, M., et al. (2014) · The Lancet HIV · doi:10.1016/s2352-3018(14)70014-1 · Cited by 628
The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo
Søgaard, O. S., Graversen, M. E., Leth, S., Olesen, R., Brinkmann, C. R., Nissen, S. K., Kjaer, A. S., Schleimann, M. H., Denton, P. W., Hey-Cunningham, W. J., et al. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1005142 · Cited by 516
Elliott, J. H., Wightman, F., Solomon, A., Ghneim, K., Ahlers, J., Cameron, M. J., Smith, M. Z., Spelman, T., McMahon, J., Velayudham, P., et al. (2014) · PLoS Pathogens · doi:10.1371/journal.ppat.1004473 · Cited by 504
Ex vivo analysis identifies effective HIV-1 latency–reversing drug combinations
Laird, G. M., Bullen, C. K., Rosenbloom, D. I. S., Martin, A. R., Hill, A. L., Durand, C. M., Siliciano, J. D., & Siliciano, R. F. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80142 · Cited by 391
Chew, G. M., Fujita, T., Webb, G. M., Burwitz, B. J., Wu, H. L., Reed, J. S., Hammond, K. B., Clayton, K. L., Ishii, N., Abdel-Mohsen, M., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005349 · Cited by 323
Metadata
- Authors
- Wei, D. G., Chiang, V., Fyne, E., Balakrishnan, M., Barnes, T., Graupe, M., Hesselgesser, J., Irrinki, A., Murry, J. P., Stepan, G., Stray, K. M., Tsai, A., Yu, H., Spindler, J., Kearney, M., Spina, C. A., McMahon, D., Lalezari, J., Sloan, D., Mellors, J., Geleziunas, R., & Cihlar, T.
- Venue
- PLoS Pathogens
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-04-10
- Volume
- 10
- Issue
- 4
- Pages
- e1004071
- ISSN
- 1553-7366 (ISSN-L)
- 1553-7374
- OpenAlex
- W2145246179
- Cited by
- 273
- References
- 55
- FWCI
- 18.23
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.